Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH434 open-label extension in multiple system atrophy
2025-524317-88-00Phase 2Authorised
- Sponsor
- Alterity Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATH-434 in multiple system atrophy (MSA), sponsored by Alterity Therapeutics. Primary endpoint: Long-term safety and tolerability. Planned start Jul 2026; status: authorised.
02
Drugs
ATH-434
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2025-524317-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524317-88-00.